Literature DB >> 12820810

Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.

Brian L Robbins1, Carrie K Wilcox, Arnold Fridland, John H Rodman.   

Abstract

OBJECTIVE: As tenofovir disoproxil fumarate substantially increases plasma concentrations of didanosine in patients with human immunodeficiency virus-1 infection, we sought to determine whether tenofovir and didanosine showed a similar intracellular interaction in human peripheral blood mononuclear cells (PBMCs).
DESIGN: Comparative in vitro incubation of two antiretrovirals in lymphocytes.
SETTING: Clinical research laboratory. MATERIAL: Radiolabeled tenofovir and didanosine in human PBMCs.
MEASUREMENTS AND MAIN RESULTS: Phosphorylation of 2 and 20 microM didanosine to dideoxyadenosine triphosphate (ddATP) was determined in quiescent and stimulated PBMCs in the presence or absence of 5 microM tenofovir. Similarly, phosphorylation of 5 microM tenofovir to tenofovir diphosphate (TFVpp) was examined in the presence or absence of 2 and 20 microM didanosine. Intracellular amounts of ddATP and TFVpp were determined by incubating PBMCs with radiolabeled tenofovir or didanosine alone and together for up to 16 hours and then separating the anabolites by high-performance liquid chromatography for quantitation. The presence of tenofovir did not affect the amount of ddATP in quiescent or stimulated PBMCs with 2 or 20 microM didanosine. In addition, didanosine did not alter the amount of TFVpp that formed. The amount of ddATP was modestly (1.5-3-fold) but consistently higher in stimulated than in quiescent PBMCs, but the amount of TFVpp did not differ.
CONCLUSION: There is no significant interaction between tenofovir and didanosine in human PBMCs as determined by the extent of formation of the phosphorylated anabolites. This suggests that adjusting didanosine dosage, when given with tenofovir, to achieve similar didanosine plasma concentrations, may be sufficient to accommodate the systemic drug interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820810     DOI: 10.1592/phco.23.6.695.32189

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  22 in total

1.  Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.

Authors:  Trevor Hawkins; Wenoah Veikley; Lucie Durand-Gasselin; Darius Babusis; Y Sunila Reddy; John F Flaherty; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

3.  Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.

Authors:  Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

Authors:  William E Delaney; Adrian S Ray; Huiling Yang; Xiaoping Qi; Shelly Xiong; Yuao Zhu; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 5.  Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.

Authors:  Ashley D Holec; Subhra Mandal; Pavan Kumar Prathipati; Christopher J Destache
Journal:  Curr HIV Res       Date:  2017       Impact factor: 1.581

Review 6.  Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Authors:  Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

7.  Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.

Authors:  Richard E Haaland; Angela Holder; Chou-Pong Pau; Alison Swaims-Kohlmeier; Carolyn Dawson; Dawn K Smith; Tebogo M Segolodi; Michael C Thigpen; Lynn A Paxton; Teresa L Parsons; Craig W Hendrix; Clyde E Hart
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

8.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Authors:  Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-15       Impact factor: 2.205

Review 9.  Antiretroviral pharmacology in mucosal tissues.

Authors:  Corbin G Thompson; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

10.  The pharmacokinetics and viral activity of tenofovir in the male genital tract.

Authors:  Manoli Vourvahis; Hiba L Tappouni; Kristine B Patterson; Ya-Chi Chen; Naser L Rezk; Susan A Fiscus; Brian P Kearney; James F Rooney; James Hui; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.